Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.

Yan ZhaoJing-Yi LiBin YangYang-Feng DingLi-Ming WuLi-Tao ZhangJin-Yan WangQian-Jin LuChun-Lei ZhangFu-Ren ZhangXiao-Hong ZhuYu-Mei LiXiao-Hua TaoQing-Chun DiaoLin-Feng LiJian-Yun LuXiao-Yong ManFu-Qiu LiXiu-Juan XiaJiao-Ran SongYing-Min JiaLi-Bo ZhangBo ChenJian-Zhong Zhang

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)

ClinicalTrials.gov identifier: NCT04893707 (15 May, 2021).

Keyphrases

atopic dermatitis
clinical trial
high intensity
early onset
phase ii
double blind
open label
study protocol
randomized controlled trial
drug induced